Acalabrutinib is a newly developed liposome inhibitor that acts on the biological process underlying intracellularuble fibrin clumping. It is similar in structure to human neutrophils but is more sensitive to the effects of acid and amino acid stimuli than neutrophils.
Studies suggest that inhibiting collagen transport causes a change in the level of fibrin produced by fibroblasts. This change in the fibrinolytic activity caused a profound increase in intracellular calcium in muscle cells (unpublished data).
These studies provide the first evidence that the mechanism underlying acalabrutinib’s effects on collagen accumulation is through inhibition of protein kinase c-reactivity.
The novel anticoagulant activity of Acalabrutinib（ACP-196） was studied in patients with mild to moderate atrial fibrillation who were receiving a treatment with atrial fibrillation-inducing agents such as rituximab, paclitaxel, and atabrine.
In patients who respond well to this first-line agents, the anticoagulant activity of acalabrutinib is maintained over several months; however, in most cases, this dose regimen is required for several years to achieve clinical benefit. The study by Fanous, et al, also indicates that the high oral dose of acalabrutinib is well tolerated by patients without serious side effects.
This study treatment with acalabrutinib resulted in significant improvement in cardiovascular disease, as measured by the coronary artery disease rating, blood pressure, and pulse rate. Patients with severe, unresectable heart disease that did not respond to other treatment options are the only group in whom the combination of anticoagulant and antiplatelet agents is particularly helpful.
The researchers explain that the increased permeability of the capillaries in the hearts of patients treated with acalabrutinib offers a natural way to deliver the drug into the myocardium, where it can do its work.
The investigators found that there was a dose-dependent effect on fibrin clots. It is not immediately obvious from the data presented here that toxins are being blocked, although the investigators used an extract of the antioxidant activity of the grape seed in their experimental oral treatment regimen.
It is not known how this toxin and anticoagulant interact to produce increased permeability of blood vessels. But the combination of the two in this novel myolytic combination has now become one of the standard therapies recommended for the treatment of arrhythmias in cardiomyopathy.
Although the researchers report good results with regard to heart disease and high levels of triglycerides, it appears that the benefits of this drug are not confined to these problems alone. They also report that even minor injuries or minor infections can be completely overcome with the administration of acalabrutinib.
Acalabrutinib is now being considered as an important and often necessary drug in many of the cardiomyopathic treatments now in use. The combination of anticoagulant and antiplatelet agents, plus rituximab, an anticoagulant, is important to improve the permeability of blood vessels. This, in turn, can improve the function of the cardiovascular system and minimizes the threat of heart failure and other complications of cardiomyopathy. You can contact us for more information.